levodopa/carbidopa orally disintegrating tablets / Generic mfg. - LARVOL DELTA

Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - P4 | N=19 | Completed | Sponsor: University of Michigan | Phase classification: P ➔ P4

Phase classification • CNS Disorders • Movement Disorders • Parkinson's Disease

The Presence of an Absence: Withdrawal of Dopaminergic Medications Leading to Neuroleptic Malignant Syndrome (ATS 2025) - "The patient's family admitted confusion regarding his home PD medications (including both carbidopa/levodopa and amantadine) in the setting of multiple, differing prescriptions...Next, the supportive, ICU care necessary included common interventions and also rare interventions like dantrolene. Finally, non-oral PD formulations or carbidopa/levodopa ODT may help prevent NMS in acute ill PD patients with severe dysphagia. Hospital pharmacies should strategically stock at least one form of them."

Acute Kidney Injury • CNS Disorders • Gastrointestinal Disorder • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease

Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - P=N/A | N=19 | Completed | Sponsor: University of Michigan | Recruiting ➔ Completed | N=40 ➔ 19 | Trial completion date: Feb 2025 ➔ Apr 2024 | Trial primary completion date: Feb 2025 ➔ Apr 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Northwestern University | N=60 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Pain

Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: University of Michigan | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Feb 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Northwestern University | Trial completion date: Jan 2023 ➔ Jan 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Pain

Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: University of Michigan | Trial completion date: Feb 2023 ➔ Feb 2024 | Trial primary completion date: Feb 2023 ➔ Feb 2024

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease from the Perspective of Treating Physicians-A Nationwide Cross-Sectional Study. (PubMed, Brain Sci) - "The Parkinson's Disease during the COVID-19 Pandemic (ParCoPa) survey was conducted as an online, nationwide, cross-sectional survey from December 2020 to March 2021 and aimed to assess the impact of the pandemic on the medical care of PD patients from the physicians' perspective...Participants offered alternative consultation options, mostly in the form of telephone (77.5%) or online (64.1%) consultations, but telephone consultations were the most accepted by patients ("broadly accepted", 40.0%). We identified pandemic-related deficits in providing care for patients with PD and areas of improvement to ensure continued care for this vulnerable patient population."

Journal • Observational data • CNS Disorders • Infectious Disease • Movement Disorders • Novel Coronavirus Disease • Parkinson's Disease • Respiratory Diseases

COVID-19 PANDEMIC AND PARKINSON’S DISEASE: IMPACT ON PATIENT CARE AND DISEASE BURDEN IN GERMANY (ADPD 2022) - " The ParCoPa (“PD in the COVID-19 pandemic”) study was conducted as a nationwide cross- sectional survey... Our analysis raises awareness that medical care for PD patients is significantly compromised in the pandemic. Telemedicine approaches and measures to minimize the risk of infection during outpatient visits may be appropriate to adequately treat this vulnerable patient population in the context of this and future pandemic situations."

Clinical • CNS Disorders • Infectious Disease • Movement Disorders • Novel Coronavirus Disease • Parkinson's Disease • Psychiatry

Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - P=N/A; N=40; Recruiting; Sponsor: University of Michigan; Trial primary completion date: Feb 2022 ➔ Feb 2023

Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Northwestern University; Not yet recruiting ➔ Recruiting

Enrollment open • Pain

Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: Northwestern University

New P2 trial • Pain

Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - P; N=40; Recruiting; Sponsor: University of Michigan

New trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Vision Response to Dopamine Replacement (clinicaltrials.gov) - P2; N=20; Terminated; Sponsor: University of Wisconsin, Madison; N=50 ➔ 20; Recruiting ➔ Terminated; Lack of funding

Clinical • Enrollment change • Trial termination